Lisata Therapeutics’ (LSTA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a research report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock.

Lisata Therapeutics Stock Down 5.5 %

Lisata Therapeutics stock opened at $2.58 on Wednesday. Lisata Therapeutics has a 52-week low of $2.19 and a 52-week high of $3.83. The firm has a market cap of $21.65 million, a PE ratio of -1.03 and a beta of 1.16. The company’s 50 day moving average is $2.86 and its two-hundred day moving average is $3.07.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.16. During the same period last year, the firm earned ($0.65) earnings per share. On average, equities research analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP grew its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.